Bavarian Nordic (BVNRY) announced today that the company has entered into an agreement with Grand River Aseptic Manufacturing, a U.S. based contract manufacturer, for fill and finish of Jynneos smallpox/monkeypox vaccine. As announced on July 15, Bavarian Nordic received an additional order for 2.5M doses the vaccine from the U.S. Biomedical Advanced Research and Development Authority, a part of the Administration for Strategic Preparedness and Response, which will be filled at Grand River using bulk vaccine already manufactured and invoiced under previous contracts with BARDA. Combined with previous orders, BARDA has requested a total of 5.5M doses for delivery in 2022 and 2023. The tech transfer of the production process to Grand River has already been initiated. “The aim is to complete the tech transfer within three months – a process which could normally take up to nine months, thus enabling GRAM to start manufacturing later this year,” Bavarian Nordic said in a statement. Chimerix (CMRX) and Siga Technologies (SIGA), other smallpox vaccine makers, are lower in afternoon trading.
previous post